With the Anglonordic Life Science Conference last week, BioEquity next week, ASGCT Annual meeting and LSX Nordic Congress around the corner, it is a good time to practice your pitching. Funds are open and now is the time to foster those new and old connections. Read on to discover what has happened this week and […]
Optimum Client’s Win Big at LSX European Lifestars Awards! Congratulations to Optimum’s clients – Asceneuron SA, Calliditas Therapeutics, DISCO Pharmaceuticals GmbH, Sofinnova Partners portfolio company Moon Surgical, Myricx Bio, and Novo Holdings, all of whom took home LSX European Lifestars awards! Plus, a special moment for Optimum’s Zoe Bolt who presented the award for Private […]
Optimum’s clients continued to gain momentum in March, starting things off on Monday with a substantial financing agreement for Heidelberg Pharma, with HealthCare Royalty for up to $115 million. On Wednesday, Heidelberg followed this with the announcement that it is to present first efficacy data from a Phase 1 clinical trial with ATAC candidate HDP-101. […]
Copenhagen-based research center is awarded up to DKK 1 billion (€134.2 million) from the Novo Nordisk Foundation to support research toward innovative approaches to the diagnosis, prevention, and treatment of cardiometabolic diseases. Read more…
Denmark’s first fully functional generally applicable quantum computer will be available in 2034. This is the objective of the ambitious Novo Nordisk Foundation Quantum Computing Programme that is being launched in collaboration with the University of Copenhagen. Quantum computers will help in developing new medicine and provide new insight into climate change and the green […]
